Clinical Trials Logo

Stage IV Non-small Cell Lung Cancer clinical trials

View clinical trials related to Stage IV Non-small Cell Lung Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03742687 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).

NCT ID: NCT03595644 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Start date: July 12, 2018
Phase: Phase 2
Study type: Interventional

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

NCT ID: NCT03559049 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease (PD), as confirmed on CT scans, after induction therapy with carboplatin/pemetrexed/pembrolizumab (CPP) triplet therapy.